Early high antibody titre convalescent plasma for hospitalised COVID-19 patients: DAWn-plasmaTimothy Devos, Geert Meyfroidt, Lucie Seyler et al.|European Respiratory Journal|2021Cited by 49
A randomized, multicentre, open-label phase II proof-of-concept trial investigating the clinical efficacy and safety of the addition of convalescent plasma to the standard of care in patients hospitalized with COVID-19: the Donated Antibodies Working against nCoV (DAWn-Plasma) trialTimothy Devos, Geert Meyfroidt, Tatjana Geukens et al.|Trials|2020Cited by 19
A randomized, multicentre, open-label phase II proof-of-concept trial investigating the clinical efficacy and safety of the addition of convalescent plasma to the standard of care in patients hospitalized with COVID-19: the Donated Antibodies Working against nCoV (DAWn-Plasma) trial.Timothy Devos, Geert Meyfroidt, Tatjana Geukens et al.|Research Square|2020Cited by 2
Correction to: A randomized, multicentre, open-label phase II proof-of-concept trial investigating the clinical efficacy and safety of the addition of convalescent plasma to the standard of care in patients hospitalized with COVID-19: the Donated Antibodies Working against nCoV (DAWn-Plasma) trialTimothy Devos, Geert Meyfroidt, Tatjana Geukens et al.|Trials|2020Cited by 1
A randomized, multicentre, open-label phase II proof-of-concept trial investigating the clinical efficacy and safety of the addition of convalescent plasma to the standard of care in patients hospitalized with COVID-19: the Donated Antibodies Working against nCoV (DAWn-Plasma) trial.Timothy Devos, Geert Meyfroidt, Tatjana Geukens et al.|Research Square|2020Cited by 1